MNE, which is based in Stockholm, Sweden, currently is the exclusive European distributor of CTD's orphan drug designated Trappsol CycloTM for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children. The MNE territory includes 44 countries in which the product is currently available on a compassionate-use "named patient" basis, following special approval from the national regulatory authorities on request from a prescribing physician.
http://ift.tt/1NDEmHW
http://ift.tt/1NDEmHW
No comments:
Post a Comment